Topic: ulcerative colitis
Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review.
The microbiome pioneer thinks the data support the rapid advance of SER-287 deeper into the clinic, although question marks about the results remain.
After a $28 million financing, Provention Bio has grabbed two IBD candidates from Janssen that should make it a double clinical-stage biotech in 2018.
The startup has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million to take a LANCL2-targeted IBD drug into the clinic.
Nestlé Health Science and Enterome have joined forces to create a microbiome-based diagnostics startup.
Atlantic Healthcare has started a rolling submission for its antisense inflammatory bowel disease drug alicaforsen enema.
Takeda has unveiled its second microbiome pact in a week to continue its gastrointestinal deal spree.
Merck KGaA spinoff Calypso Biotech has licensed its inflammatory bowel disease candidate to EA Pharma, a joint venture between Eisai and Ajinomoto.
After its $7.2 billion buyout of Receptos, Celgene has posted some encouraging midstage data for its acquired asset ozanimod for certain forms of inflammatory bowel disease.
Gilead said in a brief update that it will be canning its combined Phase II/III test of its experimental GI med GS-5745 after finding that there was “insufficient evidence of a treatment benefit” in those taking the drug.